Stephanie L Kuek, Colin Pettman, Melanie R Neeland, Joanne Harrison, Sam Mehr, Shivanthan Shanthikumar, Sean Beggs
{"title":"嗜酸性粒细胞增多症与喘息：超越哮喘的思考。","authors":"Stephanie L Kuek, Colin Pettman, Melanie R Neeland, Joanne Harrison, Sam Mehr, Shivanthan Shanthikumar, Sean Beggs","doi":"10.1183/20734735.0126-2023","DOIUrl":null,"url":null,"abstract":"<p><p><b>Primary idiopathic hypereosinophilic syndrome is a rare condition that can cause end-organ damage in multiple systems. The advent of targeted monoclonal antibodies, such as mepolizumab, provides a safe and effective steroid-sparing treatment.</b> https://bit.ly/4bgDP1u.</p>","PeriodicalId":9292,"journal":{"name":"Breathe","volume":"20 1","pages":"230126"},"PeriodicalIF":2.3000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10928552/pdf/","citationCount":"0","resultStr":"{\"title\":\"Eosinophilia and wheeze: thinking beyond asthma.\",\"authors\":\"Stephanie L Kuek, Colin Pettman, Melanie R Neeland, Joanne Harrison, Sam Mehr, Shivanthan Shanthikumar, Sean Beggs\",\"doi\":\"10.1183/20734735.0126-2023\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Primary idiopathic hypereosinophilic syndrome is a rare condition that can cause end-organ damage in multiple systems. The advent of targeted monoclonal antibodies, such as mepolizumab, provides a safe and effective steroid-sparing treatment.</b> https://bit.ly/4bgDP1u.</p>\",\"PeriodicalId\":9292,\"journal\":{\"name\":\"Breathe\",\"volume\":\"20 1\",\"pages\":\"230126\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10928552/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Breathe\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1183/20734735.0126-2023\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/3/12 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breathe","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1183/20734735.0126-2023","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/12 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
Primary idiopathic hypereosinophilic syndrome is a rare condition that can cause end-organ damage in multiple systems. The advent of targeted monoclonal antibodies, such as mepolizumab, provides a safe and effective steroid-sparing treatment. https://bit.ly/4bgDP1u.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
